Antibody-Mediated Rejection (AMR) or humoral rejection after renal transplantation is a devastating event that inevitably leads to allograft loss. Antibody-Mediated Rejection is caused by anti-donor-specific antibodies, especially anti-HLA antibodies.
Types of Antibody-Mediated Rejection:
- Hyperacute Antibody-Mediated Rejection
- Acute Antibody-Mediated Rejection
- Chronic Antibody-Mediated Rejection
Antibody-Mediated Rejection Epidemiology Segmentation
- Total prevalent cases of Antibody-Mediated Rejection
- Total diagnosed Antibody-Mediated Rejection prevalent cases
- Gender-specific diagnosed Antibody-Mediated Rejection prevalent cases
- Age-specific diagnosed Antibody-Mediated Rejection prevalent cases
- Gene-specific diagnosed Antibody-Mediated Rejection prevalent cases
Antibody-Mediated Rejection Epidemiological Insights Observed in 2020
- The total Antibody-Mediated Rejection incident cases in 7MM were observed to be 5,283.
- The Antibody-Mediated Rejection incident population in the US was found to be 3,265 in 2020.
- In 2020, The United States had the largest incident population of Antibody-Mediated Rejection in 7MM.
- Among the EU5 countries, France had the highest Antibody-Mediated Rejection incident cases whereas Germany had the lowest incident cases in 2020.
Antibody-Mediated Rejection Market Insight
Antibody-Mediated Rejection market size in the 7MM was found to be USD 90.22 million in 2020.
Antibody-Mediated Rejection Market Drivers
- Emerging therapies
- Development of personalised therapy
- Targeting of novel pathways
- Increased rate of organ donation
- Development of gene therapy
Antibody-Mediated Rejection Market Barriers
- Challenges in designing clinical trials
- High clinical burden
- Need for evidence-based treatment guidelines
Antibody-Mediated Rejection Emerging Drugs
The emerging drugs of the Antibody-Mediated Rejection market are
- Clazakizumab
- Imlifidase
- VIB4920
- Inebilizumab-cdon
- Daratumumab, and others
Antibody-Mediated Rejection Key Players
The key players working in the Antibody-Mediated Rejection market are
- CSL Behring
- Hansa Biopharma
- Viela Bio
- Janssen Biotech, and others